Literature DB >> 19326597

Transpulmonary plasma ET-1 and nitrite differences in high altitude pulmonary hypertension.

Marc M Berger1, Christoph Dehnert, Damian M Bailey, Andrew M Luks, Elmar Menold, Christian Castell, Guido Schendler, Vitalie Faoro, Heimo Mairbäurl, Peter Bärtsch, Erik R Swenson.   

Abstract

Berger, Marc M., Christoph Dehnert, Damian M. Bailey, Andrew M. Luks, Elmar Menold, Christian Castell, Guido Schendler, Vitalie Faoro, Heimo Mairbäurl, Peter Bärtsch, and Eric R. Swenson. Transpulmonary plasma ET-1 and nitrite differences in high altitude pulmonary hypertension. High Alt. Med. Biol. 10:17-24, 2009.- Thirty-four mountaineers were studied at low (110 m) and high altitude (4559 m) to evaluate if increased pulmonary artery systolic pressure (PASP) at high altitude is associated with increased pulmonary endothelin-1 (ET-1) availability and alterations in nitrite metabolism across the lung. Blood samples were obtained using central venous and radial artery catheters for plasma ET-1 and nitrite. Pulmonary blood flow was measured by inert gas rebreathing to calculate transpulmonary exchange of plasma ET-1 and nitrite, and PASP was assessed by transthoracic Doppler echocardiography. After ascent to high altitude, PASP increased from 23 +/- 4 to 39 +/- 10 mmHg. Arterial and central venous plasma ET-1 increased, while plasma nitrite did not change significantly. At low altitude there was a transpulmonary loss of plasma ET-1, but a transpulmonary gain at high altitude. In contrast was a transpulmonary gain of plasma nitrite at low altitude and a transpulmonary loss at high altitude. PASP positively correlated with a transpulmonary gain of plasma ET-1 and negatively correlated with a transpulmonary loss of plasma nitrite. These results suggest that a transpulmonary gain of plasma ET- 1 is associated with higher PASP at high altitude. Transpulmonary loss of plasma nitrite indicates either less pulmonary nitric oxide (NO) production, which contributes to higher PASP, or increased NO bioavailability arising from nitrite reduction, which may oppose ET-1-mediated vasoconstriction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19326597     DOI: 10.1089/ham.2008.1053

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  15 in total

1.  Going to altitude? Bring your vitamins!

Authors:  Carsten Lundby
Journal:  J Physiol       Date:  2010-12-01       Impact factor: 5.182

2.  High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability.

Authors:  Damian M Bailey; Christoph Dehnert; Andrew M Luks; Elmar Menold; Christian Castell; Guido Schendler; Vitalie Faoro; Mariusz Gutowski; Kevin A Evans; Sarah Taudorf; Philip E James; J McEneny; Ian S Young; Erik R Swenson; Heimo Mairbäurl; Peter Bärtsch; Marc M Berger
Journal:  J Physiol       Date:  2010-09-27       Impact factor: 5.182

3.  Assessment of right ventricular geometry and mechanics in chronic obstructive pulmonary disease patients living at high altitude.

Authors:  Tolga Sinan Güvenç; Seref Kul; Coşkun Doğan; Binnaz Zeynep Yıldırım; Yavuz Karabağ; Rengin Cetin; Yüksel Kaya; Pelin Karadağ; Aleks Değirmencioğlu; Bahattin Balcı
Journal:  Int J Cardiovasc Imaging       Date:  2014-06-21       Impact factor: 2.357

4.  Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole station.

Authors:  S Lalande; P J Anderson; A D Miller; M L Ceridon; K C Beck; K A O'Malley; J B Johnson; B D Johnson
Journal:  Eur J Appl Physiol       Date:  2011-02-16       Impact factor: 3.078

5.  Systemic Blood Predictors of Elevated Pulmonary Artery Pressure Assessed by Non-invasive Echocardiography After Acute Exposure to High Altitude: A Prospective Cohort Study.

Authors:  Shi-Zhu Bian; Chen Zhang; Rong-Sheng Rao; Xiao-Han Ding; Lan Huang
Journal:  Front Cardiovasc Med       Date:  2022-06-10

6.  Bosentan effects in hypoxic pulmonary vasoconstriction: Preliminary study in subjects with or without high altitude pulmonary edema-history.

Authors:  Isabelle Pham; Grégoire Wuerzner; Jean-Paul Richalet; Séverine Peyrard; Michel Azizi
Journal:  Pulm Circ       Date:  2012 Jan-Mar       Impact factor: 3.017

7.  Therapeutic inhibition of HIF-2α reverses polycythemia and pulmonary hypertension in murine models of human diseases.

Authors:  Manik C Ghosh; De-Liang Zhang; Wade H Ollivierre; Audrey Noguchi; Danielle A Springer; W Marston Linehan; Tracey A Rouault
Journal:  Blood       Date:  2021-05-06       Impact factor: 25.476

8.  Remote ischemic preconditioning delays the onset of acute mountain sickness in normobaric hypoxia.

Authors:  Marc M Berger; Hannah Köhne; Lorenz Hotz; Moritz Hammer; Kai Schommer; Peter Bärtsch; Heimo Mairbäurl
Journal:  Physiol Rep       Date:  2015-03

9.  Interactions among vascular-tone modulators contribute to high altitude pulmonary edema and augmented vasoreactivity in highlanders.

Authors:  Zahara Ali; Aastha Mishra; Rahul Kumar; Perwez Alam; Priyanka Pandey; Rekhbala Ram; Tashi Thinlas; Ghulam Mohammad; M A Qadar Pasha
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

10.  Polydatin attenuates hypoxic pulmonary hypertension and reverses remodeling through protein kinase C mechanisms.

Authors:  Qing Miao; Xiao-Peng Shi; Ming-Xiang Ye; Jin Zhang; Shan Miao; Si-Wang Wang; Bo Li; Xiu-Xiu Jiang; Song Zhang; Nan Hu; Juan Li; Jian Zhang
Journal:  Int J Mol Sci       Date:  2012-06-21       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.